Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial
Zita Sulyok, Rolf Fendel, Bianca Eder, Freia-Raphaella Lorenz, Natasha Kc, Matthias Karnahl, Albert Lalremruata, The T Nguyen, Jana Held, Folashade Almeine Cyntiche Adjadi, Torsten Klockenbring, Judith Flügge, Tamirat Gebru Woldearegai, Carlos Lamsfus Calle, Javier Ibáñez, Miriam Rodi, Diane Egger-Adam, Andrea Kreidenweiss, Carsten Köhler, Meral Esen, Mihály Sulyok, Anita Manoj, Thomas L Richie, B Kim Lee Sim, Stephen L Hoffman, Benjamin Mordmüller, Peter G Kremsner, Zita Sulyok, Rolf Fendel, Bianca Eder, Freia-Raphaella Lorenz, Natasha Kc, Matthias Karnahl, Albert Lalremruata, The T Nguyen, Jana Held, Folashade Almeine Cyntiche Adjadi, Torsten Klockenbring, Judith Flügge, Tamirat Gebru Woldearegai, Carlos Lamsfus Calle, Javier Ibáñez, Miriam Rodi, Diane Egger-Adam, Andrea Kreidenweiss, Carsten Köhler, Meral Esen, Mihály Sulyok, Anita Manoj, Thomas L Richie, B Kim Lee Sim, Stephen L Hoffman, Benjamin Mordmüller, Peter G Kremsner
Abstract
Immunization with Plasmodium falciparum (Pf) sporozoites under chemoprophylaxis (PfSPZ-CVac) is the most efficacious approach to malaria vaccination. Implementation is hampered by a complex chemoprophylaxis regimen and missing evidence for efficacy against heterologous infection. We report the results of a double-blinded, randomized, placebo-controlled trial of a simplified, condensed immunization regimen in malaria-naive volunteers (EudraCT-Nr: 2018-004523-36). Participants are immunized by direct venous inoculation of 1.1 × 105 aseptic, purified, cryopreserved PfSPZ (PfSPZ Challenge) of the PfNF54 strain or normal saline (placebo) on days 1, 6 and 29, with simultaneous oral administration of 10 mg/kg chloroquine base. Primary endpoints are vaccine efficacy tested by controlled human malaria infection (CHMI) using the highly divergent, heterologous strain Pf7G8 and safety. Twelve weeks following immunization, 10/13 participants in the vaccine group are sterilely protected against heterologous CHMI, while (5/5) participants receiving placebo develop parasitemia (risk difference: 77%, p = 0.004, Boschloo's test). Immunization is well tolerated with self-limiting grade 1-2 headaches, pyrexia and fatigue that diminish with each vaccination. Immunization induces 18-fold higher anti-Pf circumsporozoite protein (PfCSP) antibody levels in protected than in unprotected vaccinees (p = 0.028). In addition anti-PfMSP2 antibodies are strongly protection-associated by protein microarray assessment. This PfSPZ-CVac regimen is highly efficacious, simple, safe, well tolerated and highly immunogenic.
Conflict of interest statement
B.M. and P.G.K. received funding from the DZIF. The remaining authors declare no competing interests. All authors associated with Sanaria Inc. (N.K.C., A.M., B.K.L.S., T.L.R., and S.L.H.) have a potential conflict of interest.
Figures
References
- WHO. World Malaria Report 2019 (Geneva, 2019).
- RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685. doi: 10.1371/journal.pmed.1001685.
- RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45. doi: 10.1016/S0140-6736(15)60721-8.
- Clyde DF, McCarthy VC, Miller RM, Hornick RB. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am. J. Med. Sci. 1973;266:398–403. doi: 10.1097/00000441-197312000-00001.
- Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Letter: Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 1974;68:258–259. doi: 10.1016/0035-9203(74)90129-1.
- Hoffman SL, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 2010;6:97–106. doi: 10.4161/hv.6.1.10396.
- Hoffman SL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 2002;185:1155–1164. doi: 10.1086/339409.
- Lyke KE, et al. Attenuated PfSPZ vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc. Natl Acad. Sci. USA. 2017;114:2711–2716. doi: 10.1073/pnas.1615324114.
- Sissoko MS, et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 2017;17:498–509. doi: 10.1016/S1473-3099(17)30104-4.
- Epstein JE, et al. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight. 2017;2:e89154. doi: 10.1172/jci.insight.89154.
- Seder RA, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359–1365. doi: 10.1126/science.1241800.
- Mordmüller B, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445–449. doi: 10.1038/nature21060.
- Roestenberg M, et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 2009;361:468–477. doi: 10.1056/NEJMoa0805832.
- Roestenberg M, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011;377:1770–1776. doi: 10.1016/S0140-6736(11)60360-7.
- Schats R, et al. Heterologous protection against malaria after immunization with Plasmodium falciparum sporozoites. PLoS ONE. 2015;10:e0124243. doi: 10.1371/journal.pone.0124243.
- Walk J, et al. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial. BMC Med. 2017;15:168. doi: 10.1186/s12916-017-0923-4.
- Dent AE, et al. Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya. J. Infect. Dis. 2015;212:1429–1438. doi: 10.1093/infdis/jiv224.
- Felgner PL, et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci. Rep. 2013;3:3549. doi: 10.1038/srep03549.
- Kobayashi, T. et al. Distinct antibody signatures associated with different malaria transmission intensities in Zambia and Zimbabwe. mSphere4, 10.1128/mSphereDirect.00061-19 (2019).
- Obiero, J. M. et al. Antibody biomarkers associated with sterile protection induced by controlled human malaria infection under chloroquine prophylaxis. mSphere4, 10.1128/mSphereDirect.00027-19 (2019).
- Moser KA, et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med. 2020;12:6. doi: 10.1186/s13073-019-0708-9.
- Mordmüller B, et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar. J. 2015;14:117. doi: 10.1186/s12936-015-0628-0.
- Bijker EM, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc. Natl Acad. Sci. USA. 2013;110:7862–7867. doi: 10.1073/pnas.1220360110.
- Cockburn IA, Seder RA. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 2018;19:1199–1211. doi: 10.1038/s41590-018-0228-6.
- Epstein JE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science. 2011;334:475–480. doi: 10.1126/science.1211548.
- Julien J-P, Wardemann H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat. Rev. Immunol. 2019;19:761–775. doi: 10.1038/s41577-019-0209-5.
- Wang LT, et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity. 2020;53:733–744.e738. doi: 10.1016/j.immuni.2020.08.014.
- Roth A, et al. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum. Nat. Commun. 2018;9:1837. doi: 10.1038/s41467-018-04221-9.
- Longley RJ, et al. Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Sci. Rep. 2015;5:11820. doi: 10.1038/srep11820.
- Eacret JS, Gonzales DM, Franks RG, Burns JM., Jr. Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody. Sci. Rep. 2019;9:9022. doi: 10.1038/s41598-019-45440-4.
- Nagaoka H, et al. PfMSA180 is a novel Plasmodium falciparum vaccine antigen that interacts with human erythrocyte integrin associated protein (CD47) Sci. Rep. 2019;9:5923. doi: 10.1038/s41598-019-42366-9.
- Bhattacharyya M, Chakrabarti S. Identification of important interacting proteins (IIPs) in Plasmodium falciparum using large-scale interaction network analysis and in-silico knock-out studies. Malar. J. 2015;14:70. doi: 10.1186/s12936-015-0562-1.
- Bousema, T. & Drakeley, C. Determinants of malaria transmission at the population level. Cold Spring Harb. Perspect. Med.7, 10.1101/cshperspect.a025510 (2017).
- WHO. WHO Preferred Product Characteristics (PPC) for Malaria Vaccines (WHO, Geneva, 2014).
- Burkot TR, Williams JL, Schneider I. Infectivity to mosquitoes of Plasmodium falciparum clones grown in vitro from the same isolate. Trans. R. Soc. Trop. Med. Hyg. 1984;78:339–341. doi: 10.1016/0035-9203(84)90114-7.
- Maskus DJ, et al. Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. Sci. Rep. 2016;6:39462. doi: 10.1038/srep39462.
- Taghavian, O. et al. Antibody profiling by proteome microarray with multiplex isotype detection reveals overlap between human and Aotus nancymaae controlled malaria infections. Proteomics18, 10.1002/pmic.201700277 (2018).
Source: PubMed